| abstract |
The present disclosure provides a method of treating a disease or disorder associated with LGL and/or NK cells using an antibody that binds to cell surface proteins on LGL and/or NK cells and comprises enhanced ADCC activity, LGL and/or NK cells It relates to a method for reducing or depleting , and to a method for inducing ADCC activity. The present invention also provides a method for reducing the number of large granular lymphocytes and natural killer cells in a human subject upon administration of a CD94 or CD57 or NKG2A binding molecule consisting of a portion specifically binding to CD94 or CD57 or NKG2A receptor and an immunoglobulin Fc portion or How to deplete it. In a specific embodiment, the methods of the invention deplete or reduce the number of large granular lymphocytes and natural killer cells in the spleen, blood, bone marrow, joint, or other tissue. |